Registration number:
Bio-genics limited
for the Period from 1 December 2023 to 31 August 2024
Bio-genics limited
Contents
|
Company Information |
|
|
Director's Report |
|
|
Accountants' Report |
|
|
Statement of Comprehensive Income |
|
|
Statement of Financial Position |
|
|
Notes to the Unaudited Financial Statements |
|
|
Detailed Statement of Comprehensive Income |
Bio-genics limited
Company Information
|
Director |
Mr P Collins |
|
Registered office |
|
|
Accountants |
|
Bio-genics limited
Director's Report for the Period from 1 December 2023 to 31 August 2024
The director presents his report and the financial statements for the period from 1 December 2023 to 31 August 2024.
Director of the company
The director who held office during the period was as follows:
Small companies provision statement
This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
Approved and authorised by the
|
|
Chartered
Certified
Accountants' Report to the
Director
on the Preparation of the Unaudited Statutory Accounts of
Bio-genics limited
for the
Period
Ended
31 August 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Bio-genics limited for the period ended 31 August 2024 as set out on pages 4 to 8 from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/gb/en/member/standards/rules-and-standards/rulebook.html.
This report is made solely to the Board of Directors of Bio-genics limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Bio-genics limited and state those matters that we have agreed to state to the Board of Directors of Bio-genics limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/
october/factsheet-163-audit-exempt-companies.html. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Bio-genics limited and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that Bio-genics limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Bio-genics limited. You consider that Bio-genics limited is exempt from the statutory audit requirement for the period.
We have not been instructed to carry out an audit or a review of the accounts of Bio-genics limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
......................................
Chartered Certified Accountants
West Wickham
Kent
BR4 0LS
Bio-genics limited
Statement of Comprehensive Income for the Period from 1 December 2023 to 31 August 2024
|
Note |
2024 |
2023 |
|
|
Turnover |
|
|
|
|
Cost of sales |
( |
( |
|
|
Gross profit |
|
|
|
|
Administrative expenses |
( |
( |
|
|
Operating loss |
(13) |
(75) |
|
|
Loss before tax |
( |
( |
|
|
Loss for the financial period |
( |
( |
The above results were derived from continuing operations.
The company has no recognised gains or losses for the period other than the results above.
Bio-genics limited
(Registration number: 03665155)
Statement of Financial Position as at 31 August 2024
|
Note |
2024 |
2023 |
|
|
Fixed assets |
|||
|
Tangible assets |
- |
|
|
|
Current assets |
|||
|
Cash at bank and in hand |
|
|
|
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Profit and loss account |
|
|
|
|
Shareholders' funds |
|
|
For the financial period ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
|
• |
|
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.
Approved and authorised by the
|
|
Bio-genics limited
Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024
|
General information |
The company is a private company limited by share capital, incorporated in United Kingdon.
The address of its registered office is:
England
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
The financial statements are prepared in sterling which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. |
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. |
Revenue recognition
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.
Bio-genics limited
Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024
Tangible assets
Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Computer equipment |
25% on reducing balance |
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities
Financial instruments
Recognition and measurement
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
|
Staff numbers |
The average number of persons employed by the company (including the director) during the period, was
|
Loss before tax |
Arrived at after charging/(crediting)
|
2024 |
2023 |
|
|
Depreciation expense |
|
|
Bio-genics limited
Notes to the Unaudited Financial Statements for the Period from 1 December 2023 to 31 August 2024
|
Tangible assets |
|
Office equipment |
Total |
|
|
Cost or valuation |
||
|
At 1 December 2023 |
|
|
|
At 31 August 2024 |
|
|
|
Depreciation |
||
|
At 1 December 2023 |
|
|
|
Charge for the period |
|
|
|
At 31 August 2024 |
|
|
|
Carrying amount |
||
|
At 31 August 2024 |
- |
- |
|
At 30 November 2023 |
|
|
|
Creditors |
Creditors: amounts falling due within one year
|
2024 |
2023 |
|
|
Due within one year |
||
|
Accruals and deferred income |
|
|
|
Other creditors |
|
|
|
|
|
|
Reserves |
Profit and loss account:
This reserve records retained earnings and accumulated losses.
Bio-genics limited
Detailed Statement of Comprehensive Income for the Period from 1 December 2023 to 31 August 2024
|
2024 |
2023 |
|
|
Turnover |
||
|
Fees and commission received |
12,060 |
7,752 |
|
12,060 |
7,752 |
|
|
Cost of sales |
||
|
Medical supplies |
74 |
532 |
|
74 |
532 |
|
|
Gross profit |
11,986 |
7,220 |
|
Gross profit (%) |
99.39% |
93.14% |
|
Administrative expenses |
||
|
Wages |
2,500 |
650 |
|
Insurance |
562 |
627 |
|
Use of residence as office |
600 |
600 |
|
Telephone |
521 |
489 |
|
Postage, stationery & advertising |
21 |
344 |
|
Sundry expenses |
356 |
- |
|
Motor expenses |
2,517 |
1,415 |
|
Traveling |
400 |
12 |
|
Accountancy fees |
1,600 |
1,260 |
|
Consultancy |
980 |
- |
|
Professional fees |
1,676 |
1,690 |
|
Bank charges |
218 |
192 |
|
Depreciation of computer equipment |
48 |
16 |
|
11,999 |
7,295 |
|
|
Operating loss |
(13) |
(75) |
|
Loss before tax |
(13) |
(75) |